CNX-774BTK inhibitor, orally active, irreversible and selective CAS# 1202759-32-7 |
- PF-4708671
Catalog No.:BCC5031
CAS No.:1255517-76-0
- BIX 02565
Catalog No.:BCC4303
CAS No.:1311367-27-7
- BI-D1870
Catalog No.:BCC5030
CAS No.:501437-28-1
- FMK
Catalog No.:BCC1580
CAS No.:821794-92-7
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 1202759-32-7 | SDF | Download SDF |
| PubChem ID | 59174579 | Appearance | Powder |
| Formula | C26H22FN7O3 | M.Wt | 499.5 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 45 mg/mL (90.09 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 4-[4-[[5-fluoro-4-[3-(prop-2-enoylamino)anilino]pyrimidin-2-yl]amino]phenoxy]-N-methylpyridine-2-carboxamide | ||
| SMILES | CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC3=NC=C(C(=N3)NC4=CC(=CC=C4)NC(=O)C=C)F | ||
| Standard InChIKey | VVLHQJDAUIPZFH-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C26H22FN7O3/c1-3-23(35)31-17-5-4-6-18(13-17)32-24-21(27)15-30-26(34-24)33-16-7-9-19(10-8-16)37-20-11-12-29-22(14-20)25(36)28-2/h3-15H,1H2,2H3,(H,28,36)(H,31,35)(H2,30,32,33,34) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | CNX-774 is a potent, selective, and orally available small molecule inhibitor of Btk (IC50< 1 nM) that forms a ligand-directed covalent bond with Cys-481, a non-conserved amino acid within the active site of the enzyme.
IC50 Value: <1 nM [1]
Target: Btk Kinase
In biochemical assays, CNX-774 has demonstrated potent inhibition of Btk with an IC50 of <1nM in a continuous-read assay. The covalent bonding of CNX-774 to Btk was confirmed by incubating recombinant Btk protein with a 10-fold molar excess of CNX-774 for 1 hour at room temperature and analysis by MALDI-TOF MS. A shift of protein mass corresponding to the molecular weight of CNX-774 confirmed the covalent bonding of CNX-774 to Btk. Digestion of the covalently bonded Btk with pepsin followed by MSMS analysis established the bonding of CNX-774 to Cys-481. Cellular potency as well as prolonged duration of action of CNX-774 was demonstrated in Ramos cells by using a biotinylated covalent probe that targets the same Cysteine residue as CNX-774.
CNX-774 was found to be >90% extractable after 2 hrs of incubation in both rat and human whole blood. These results demonstrate that CNX-774 has potent inhibitory activity towards the intended target, Btk, while achieving remarkable specificity in a variety of assays designed to assess off-target reactivity towards abundant cellular thiols and blood proteins. References: | |||||
CNX-774 Dilution Calculator
CNX-774 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.002 mL | 10.01 mL | 20.02 mL | 40.04 mL | 50.0501 mL |
| 5 mM | 0.4004 mL | 2.002 mL | 4.004 mL | 8.008 mL | 10.01 mL |
| 10 mM | 0.2002 mL | 1.001 mL | 2.002 mL | 4.004 mL | 5.005 mL |
| 50 mM | 0.04 mL | 0.2002 mL | 0.4004 mL | 0.8008 mL | 1.001 mL |
| 100 mM | 0.02 mL | 0.1001 mL | 0.2002 mL | 0.4004 mL | 0.5005 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
CNX-774 is an orally active and selective inhibitor of BTK with IC50 value of <1 nM.
Bruton’s tyrosine kinase (BTK) is an important enzyme in the B-cell antigen receptor (BCR) signaling pathway and also plays an important role in mast cell activation and B cell maturation.
CNX-774 is an orally active, irreversible and selective BTK inhibitor with IC50 value of <1 nM. CNX-774 formed covalent bond with the Cys481 residue within the ATP binding site of BTK. In cellular assays, CNX-774 inhibited BTK with IC50 values of 1-10 nM [1].
Reference:
[1]. Akinleye A, Chen Y, Mukhi N, et al. Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol, 2013, 6: 59.
- AVL-292
Catalog No.:BCC1385
CAS No.:1202757-89-8
- CGS 21680
Catalog No.:BCC1475
CAS No.:120225-54-9
- 1beta-Hydroxyeuscaphic acid
Catalog No.:BCN3517
CAS No.:120211-98-5
- Tenidap
Catalog No.:BCC7419
CAS No.:120210-48-2
- NMS-P715
Catalog No.:BCC6373
CAS No.:1202055-34-2
- Clopidogrel Related Compound C
Catalog No.:BCN2689
CAS No.:120202-71-3
- Clopidogrel
Catalog No.:BCC2497
CAS No.:120202-66-6
- 3,4-Dihydroxycinnamamide
Catalog No.:BCN6090
CAS No.:1202-41-1
- Cynoglossamine
Catalog No.:BCN1970
CAS No.:120193-39-7
- TCS 2210
Catalog No.:BCC7798
CAS No.:1201916-31-5
- MLN9708
Catalog No.:BCC2091
CAS No.:1201902-80-8
- Vinflunine Tartrate
Catalog No.:BCC4602
CAS No.:1201898-17-0
- Salvinolone
Catalog No.:BCN3215
CAS No.:120278-22-0
- 4-Hydroxysapriparaquinone
Catalog No.:BCN4806
CAS No.:120278-25-3
- Dorzolamide
Catalog No.:BCC4287
CAS No.:120279-96-1
- CX-6258
Catalog No.:BCC1504
CAS No.:1202916-90-2
- Citroside A
Catalog No.:BCN7294
CAS No.:120330-44-1
- DASA-58
Catalog No.:BCC6522
CAS No.:1203494-49-8
- Cyclotraxin B
Catalog No.:BCC6357
CAS No.:1203586-72-4
- AS 1949490
Catalog No.:BCC7762
CAS No.:1203680-76-5
- Jionoside B1
Catalog No.:BCN2858
CAS No.:120406-37-3
- Biapenem
Catalog No.:BCC1071
CAS No.:120410-24-4
- AZD1208
Catalog No.:BCC2079
CAS No.:1204144-28-4
- Icotinib Hydrochloride
Catalog No.:BCC1639
CAS No.:1204313-51-8
BTK inhibition is a potent approach to block IgE-mediated histamine release in human basophils.[Pubmed:28328081]
Allergy. 2017 Nov;72(11):1666-1676.
BACKGROUND: Recent data suggest that Bruton's tyrosine kinase (BTK) is an emerging therapeutic target in IgE receptor (IgER)-cross-linked basophils. METHODS: We examined the effects of four BTK inhibitors (ibrutinib, dasatinib, AVL-292, and CNX-774) on IgE-dependent activation and histamine release in blood basophils obtained from allergic patients (n=11) and nonallergic donors (n=5). In addition, we examined the effects of these drugs on the growth of the human basophil cell line KU812 and the human mast cell line HMC-1. RESULTS: All four BTK blockers were found to inhibit anti-IgE-induced histamine release from basophils in nonallergic subjects and allergen-induced histamine liberation from basophils in allergic donors. Drug effects on allergen-induced histamine release were dose dependent, with IC50 values ranging between 0.001 and 0.5 mumol/L, and the following rank order of potency: ibrutinib>AVL-292>dasatinib>CNX-774. The basophil-targeting effect of ibrutinib was confirmed by demonstrating that IgE-dependent histamine release in ex vivo blood basophils is largely suppressed in a leukemia patient treated with ibrutinib. Dasatinib and ibrutinib were also found to counteract anti-IgE-induced and allergen-induced upregulation of CD13, CD63, CD164, and CD203c on basophils, whereas AVL-292 and CNX-774 showed no significant effects. Whereas dasatinib and CNX-774 were found to inhibit the growth of HMC-1 cells and KU812 cells, no substantial effects were seen with ibrutinib or AVL-292. CONCLUSIONS: BTK-targeting drugs are potent inhibitors of IgE-dependent histamine release in human basophils. The clinical value of BTK inhibition in the context of allergic diseases remains to be determined.
Ibrutinib and novel BTK inhibitors in clinical development.[Pubmed:23958373]
J Hematol Oncol. 2013 Aug 19;6:59.
Small molecule inhibitors targeting dysregulated pathways (RAS/RAF/MEK, PI3K/AKT/mTOR, JAK/STAT) have significantly improved clinical outcomes in cancer patients. Recently Bruton's tyrosine kinase (BTK), a crucial terminal kinase enzyme in the B-cell antigen receptor (BCR) signaling pathway, has emerged as an attractive target for therapeutic intervention in human malignancies and autoimmune disorders. Ibrutinib, a novel first-in-human BTK-inhibitor, has demonstrated clinical effectiveness and tolerability in early clinical trials and has progressed into phase III trials. However, additional research is necessary to identify the optimal dosing schedule, as well as patients most likely to benefit from BTK inhibition. This review summarizes preclinical and clinical development of ibrutinib and other novel BTK inhibitors (GDC-0834, CGI-560, CGI-1746, HM-71224, CC-292, and ONO-4059, CNX-774, LFM-A13) in the treatment of B-cell malignancies and autoimmune disorders.
